Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer.

Inclusion Criteria:

* Histologically proven adenocarcinoma of the esophagus
* Age \>18 years
* UICC T2-4 N0-2 M0, potentially resectable disease
* Patient discussed at tumour board (multidisciplinary team meeting)
* No evident tumor invasion in nearby regions like aorta or trachea
* WHO performance status 0-2
* Less than 10 % weight loss in the past 6 months
* Laboratory requirements within 7 days prior to enrollment (start chemoradiotherapy):
* Haematology:

  * haemoglobin \>10g/dl
  * absolute neutrophils ≥ 1.5 x 109/L
  * platelets ≥ 100x109/L
* Biochemistry:

  * bilirubin within institutional normal limits
  * AST(SGOT)/ALT (SGPT) ≤ 2.5 institutional upper limit
  * Creatinine clearance ≥ 60 ml/min
* Willing and able to comply with the study prescriptions
* No history of prior thoracic radiotherapy
* No severe chronic obstructive pulmonary disease with hypoxemia or in the opinion of the investigator any physiological state leading to hypoxemia
* Women should not be pregnant or lactating
* No known infection with HIV, hepatitis B or C or any other active infection
* Normal ECG with careful evaluation of QT/QTc
* Have given written informed consent before patient registration

Exclusion Criteria:

* Recent (\< 3 months) severe cardiac disease (arrhythmia, congestive heart failure, infarction)
* Patients with difficult peripheral intravenous access
* History of prior thoracic radiotherapy
* severe chronic obstructive pulmonary disease with hypoxemia or in the opinion of the investigator any physiological state leading to hypoxemia
* Women who are pregnant or lactating
* Known infection with HIV, hepatitis B or C or any other active infection